Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All extracted claims are described as absent from the provided FDA label content, and none conflict with on-label safety, dosing, contraindications, warnings, or other prescribing-information requirements.
Category Scores
Accurate Statements
Ngenla (somatrogon ghk) patent expiration depends on the specific patent numbers.
Absent from the label (no FDA labeling claim contradicted).
Ngenla (somatrogon ghk) patent expiration depends on the country.
Absent from the label (no FDA labeling claim contradicted).
Patent and exclusivity timelines differ across the U.S., EU, UK, and other markets.
Absent from the label (no FDA labeling claim contradicted).
An exact Ngenla patent expiration date cannot be stated reliably without specific patent details and jurisdictions.
Absent from the label (no FDA labeling claim contradicted).
The real 'patent expiration' for Ngenla requires knowing the jurisdiction.
Absent from the label (no FDA labeling claim contradicted).
The real 'patent expiration' for Ngenla requires knowing the specific patents covering the drug (composition-of-matter vs. formulation vs. method-of-use).
Absent from the label (no FDA labeling claim contradicted).
Whether the question means 'patent expiration' or 'market exclusivity' matters because market exclusivity is often longer than the first patent expiry.
Absent from the label (no FDA labeling claim contradicted).
Pediatric or other regulatory exclusivity extensions can extend effective protection beyond the baseline patent term.
Absent from the label (no FDA labeling claim contradicted).
Parts of the drug’s protection can expire at different times (e.g., one patent family might expire earlier than another).
Absent from the label (no FDA labeling claim contradicted).
A competitor may be blocked from launching in a market until the remaining patents or exclusivity protections expire even if some patents have already lapsed.
Absent from the label (no FDA labeling claim contradicted).
To provide a specific Ngenla timeline, the relevant country and whether the user means patent expiration or market exclusivity are needed.
Absent from the label (no FDA labeling claim contradicted).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims address patent/exclusivity mechanics and do not make or omit safety-critical prescribing-information statements (e.g., contraindications, boxed warnings, dosing, administration, monitoring).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No prescribing-information alignment issues found; claims are external to FDA label content.
Suggested Improvement
If the goal is FDA-label accuracy, limit responses to information present in the FDA-approved prescribing information (e.g., indications, dosing, safety, warnings) rather than patent/exclusivity timelines that are not covered in the label.